SG11201505076UA - Liquid topical pharmaceutical nano-emulsion formulations - Google Patents

Liquid topical pharmaceutical nano-emulsion formulations

Info

Publication number
SG11201505076UA
SG11201505076UA SG11201505076UA SG11201505076UA SG11201505076UA SG 11201505076U A SG11201505076U A SG 11201505076UA SG 11201505076U A SG11201505076U A SG 11201505076UA SG 11201505076U A SG11201505076U A SG 11201505076UA SG 11201505076U A SG11201505076U A SG 11201505076UA
Authority
SG
Singapore
Prior art keywords
topical pharmaceutical
emulsion formulations
liquid topical
nano
pharmaceutical nano
Prior art date
Application number
SG11201505076UA
Other languages
English (en)
Inventor
Frederick L Jordan
Chris Jordan
Original Assignee
Jrx Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jrx Biotechnology Inc filed Critical Jrx Biotechnology Inc
Publication of SG11201505076UA publication Critical patent/SG11201505076UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201505076UA 2012-12-31 2013-12-27 Liquid topical pharmaceutical nano-emulsion formulations SG11201505076UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261748036P 2012-12-31 2012-12-31
US201361758726P 2013-01-30 2013-01-30
PCT/US2013/077985 WO2014106048A2 (en) 2012-12-31 2013-12-27 Liquid topical pharmaceutical nano-emulsion formulations

Publications (1)

Publication Number Publication Date
SG11201505076UA true SG11201505076UA (en) 2015-07-30

Family

ID=51022202

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201505076UA SG11201505076UA (en) 2012-12-31 2013-12-27 Liquid topical pharmaceutical nano-emulsion formulations

Country Status (10)

Country Link
US (2) US20150374835A1 (https=)
EP (1) EP2938324B1 (https=)
JP (1) JP6403686B2 (https=)
KR (1) KR20150102058A (https=)
CN (2) CN105209011B (https=)
BR (1) BR112015015788A2 (https=)
EA (1) EA201591015A1 (https=)
ES (1) ES2969933T3 (https=)
SG (1) SG11201505076UA (https=)
WO (1) WO2014106048A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
US11007161B1 (en) 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization
DK3518672T3 (da) 2016-09-29 2026-02-09 Jrx Biotechnology Inc Fremgangsmåder til ændring af plantevækst og reducering af planters vandforbrug
PL3558269T3 (pl) 2016-12-21 2024-11-18 Dukebox Spółka Z Ograniczoną Odpowiedzialnością Sposób wytwarzania emulsji woda w oleju nanocząsteczek paracetamolu
US11634368B2 (en) * 2018-03-28 2023-04-25 Jrx Biotechnology, Inc. Agricultural compositions
KR102117651B1 (ko) 2018-04-27 2020-06-02 대구가톨릭대학교산학협력단 항산화, 주름개선 또는 염증개선용 한방 조성물 및 이를 포함하는 화장료 조성물

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374766A (en) 1982-06-01 1983-02-22 Charles Of The Ritz Group Ltd. Combined allantoin-hydrolyzed animal protein product and method
US4973473A (en) 1989-06-23 1990-11-27 Revlon, Inc. Skin care preparation
IT1232318B (it) 1989-09-07 1992-01-28 Crinos Industria Farmaco Composizioni ad uso topico contenenti acidi nucleici depolimerizzati per la cosmesi della pelle e del corpo.
US5153174A (en) 1989-10-30 1992-10-06 Union Carbide Chemicals & Plastics Inc. Polymer mixtures useful in skin care
JP3172177B2 (ja) 1990-11-14 2001-06-04 イミュー プロダクツ ウェスターン オーストレイリア ピーティーワイ． リミテッド エミュー油から誘導した抗炎性混合物
US5297562A (en) 1991-04-01 1994-03-29 President And Fellows Of Harvard College Method for detecting and treating Alzheimer's disease
IL101387A (en) 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US5614212A (en) 1992-04-08 1997-03-25 International Medical Associates, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5318960A (en) 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
KR940021073A (ko) 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
US6103246A (en) 1993-06-03 2000-08-15 Tisdale; Carrie J. Creams and lotions containing emu oil
US5840746A (en) 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5472713A (en) 1994-11-23 1995-12-05 Elf Resources, Inc. Therapeutic uses of emu oil
US5716625A (en) 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5744128A (en) 1995-05-03 1998-04-28 Holick; Michael F. Use of emu oil for stimulating skin and hair growth
AUPN531195A0 (en) 1995-09-11 1995-10-05 J.W. Broadbent Nominees Pty. Ltd. Lipid extract having anti-inflamatory activity
US5939082A (en) 1995-11-06 1999-08-17 The Procter & Gamble Company Methods of regulating skin appearance with vitamin B3 compound
IT1289845B1 (it) 1996-01-10 1998-10-16 Guido Paduano Formula per il trattamento della cute e suoi impieghi
US5891857A (en) 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
JP2000506062A (ja) 1996-03-01 2000-05-23 株式会社 荏原製作所 電子ビーム照射による脱硫方法及び装置
US5891651A (en) 1996-03-29 1999-04-06 Mayo Foundation For Medical Education And Research Methods of recovering colorectal epithelial cells or fragments thereof from stool
US5861268A (en) 1996-05-23 1999-01-19 Biomide Investment Limited Partnership Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
US5708038A (en) 1996-06-13 1998-01-13 Univera Pharmaceuticals, Inc. Method of using aloe vera as a biological vehicle
US5698227A (en) 1996-07-23 1997-12-16 Rivlin; Daniel Compositions comprising lidocaine and emu oil and methods of use thereof
JP2001516340A (ja) 1996-12-31 2001-09-25 アメリカン、メディカル、リサーチ、インコーポレーテッド 抗菌性、抗ウイルス性、防腐性、および治癒性が持続する皮膚用製品
AU6046198A (en) 1997-01-31 1998-08-25 Kenneth Hoyt Use of oil from emu or rhea birds as trans-membrane carriers for delivery of drugs, peptides and vaccines
US5945446A (en) 1997-02-10 1999-08-31 Laubc Biochemicals, Corporation Process for preparing synthetic soil-extract materials and medicaments based thereon
ATE265847T1 (de) 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
US5885597A (en) 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
ID25908A (id) 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
CA2331640A1 (en) 1998-05-07 1999-11-11 Elan Corporation Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
AR018376A1 (es) * 1998-05-26 2001-11-14 Novartis Ag Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
AU4972599A (en) 1998-07-07 2000-01-24 Transdermal Technologies, Inc. Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
US7220427B2 (en) 1998-07-08 2007-05-22 Oryxe Mixture for transdermal delivery of low and high molecular weight compounds
AU5093199A (en) 1998-07-08 2000-02-01 Oryxe Transdermal delivery system
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
FR2787703B1 (fr) * 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US20060121103A1 (en) 2000-05-11 2006-06-08 Kenneth Kirby Transdermal delivery system
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
MXPA06003887A (es) * 2003-10-10 2006-08-11 Oryxe Compuestos transdermicos de alto y bajo peso molecular.
US20080154210A1 (en) * 2004-05-28 2008-06-26 Oryxe Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds
WO2006041538A2 (en) 2004-05-28 2006-04-20 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
US20050271752A1 (en) * 2004-06-04 2005-12-08 Roth Ivar E Antifungal products and method of use
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
WO2006113668A1 (en) * 2005-04-15 2006-10-26 University Of South Florida A method of transdermal drug delivery using hyaluronic acid nanoparticles
US20070264346A1 (en) 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
EP2001439A2 (en) 2006-03-07 2008-12-17 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
WO2009021526A1 (de) * 2007-07-25 2009-02-19 S & V Technologies Ag Hyaluronsäuredispersion, herstellung und anwendung
GB2451811A (en) * 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
DE102008034944B4 (de) * 2008-07-26 2017-03-16 Arivine Pharma Ag Mikroemulsion
CN102389401B (zh) 2011-11-22 2013-05-22 陆荣政 一种右旋布洛芬颗粒及其制备方法

Also Published As

Publication number Publication date
US12285487B2 (en) 2025-04-29
US20150374835A1 (en) 2015-12-31
WO2014106048A2 (en) 2014-07-03
HK1218723A1 (zh) 2017-03-10
BR112015015788A2 (pt) 2017-07-11
KR20150102058A (ko) 2015-09-04
EP2938324B1 (en) 2023-11-08
US20200009257A1 (en) 2020-01-09
EP2938324A2 (en) 2015-11-04
WO2014106048A3 (en) 2014-08-21
JP2016508141A (ja) 2016-03-17
ES2969933T3 (es) 2024-05-23
EA201591015A1 (ru) 2016-05-31
CN105209011A (zh) 2015-12-30
HK1216719A1 (en) 2016-12-02
JP6403686B2 (ja) 2018-10-10
EP2938324A4 (en) 2016-09-28
CN110201180A (zh) 2019-09-06
CN105209011B (zh) 2019-06-25

Similar Documents

Publication Publication Date Title
IL235409A0 (en) Topical non-aqueous pharmaceutical formulations
ZA201409269B (en) Liquid formulation
ZA201406233B (en) Pharmaceutical composition and administration thereof
ZA201407373B (en) Novel pharmaceutical formulations
ZA201501930B (en) Pharmaceutical composition
IL237804A0 (en) Liquid formulations of apixaban
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
SG11201505076UA (en) Liquid topical pharmaceutical nano-emulsion formulations
ZA201409020B (en) Pharmaceutical formulation
EP2839825A4 (en) LIQUID COSMETIC PREPARATION
AP2015008208A0 (en) Pharmaceutical administration forms comprising
GB201201162D0 (en) Liquid cosmetic composition
DK2735305T3 (da) Stabiliserede flydende farmaceutiske præparater
ZA201405925B (en) Pharmaceutical formulation having improved stability
LT3473255T (lt) Farmacinė vaisto forma, apimanti ciklezonidą
ZA201502987B (en) Pharmaceutical composition
IL235988B (en) Drug composition is based on genotype or phenotype
EP2851074A4 (en) ANALGETIC PHARMACEUTICAL COMPOSITION
SG11201504068UA (en) Orally administered liquid formulation
HUE046492T2 (hu) Kurkumint tartalmazó gyógyászati készítmény
ZA201406407B (en) Pharmaceutical formulation containing flupirtin
GB201221125D0 (en) Pharmaceutial formulations
GB201204597D0 (en) Topical pharmaceutical formulation
GB201211403D0 (en) Pharmaceutical formulations
GB201211406D0 (en) Pharmaceutical formulations